Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes

Acta Diabetologica

Volumn 51, Issue 4, 2014, Pages 567-575

  Calanna, Salvatore ^a   Scicali, Roberto ^a   Di Pino, Antonino ^a   Knop, Filip Krag ^b,c   Piro, Salvatore ^a   Rabuazzo, Agata Maria ^a   Purrello, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glucagon; Incretin effect; Insulin secretion; Prediabetes; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN;

BLOOD; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC USE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PREDIABETIC STATE;

BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-SECRETING CELLS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 84905906980     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0555-5     Document Type: Article

References (33)

1. American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67-S74. doi:10.2337/dc13-S067
2. Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta
3. Centers for Disease Control and Prevention (2008) National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta
4. Edelman D, Olsen MK, Dudley TK et al (2004) Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med 19:1175-1180. doi:10.1111/j.1525- 1497.2004.40178.x (Pubitemid 40041381)
5. Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340-1348. doi:10.2337/db07-1315
6. Faerch K, Vaag A, Holst JJ et al (2008) Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 51:853-861. doi:10.1007/s00125-008-0951-x
7. Zhang F, Tang X, Cao H et al (2012) Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci 9:574-581. doi:10.7150/ijms.4128
8. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19. doi:10.1007/s00125-002-1009-0
9. D'Alessio D (2011) The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 13(Suppl 1):126-132. doi:10.1111/j.1463-1326.2011. 01449.x
10. Calanna S, Christensen M, Holst JJ et al (2013) Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. doi:10.1007/s00125- 013-2841-0
11. Calanna S, Christensen M, Holst JJ et al (2013) Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 36:3346-3352. doi:10.2337/dc13-0465
12. Nauck MA, Homberger E, Siegel EG et al (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498 (Pubitemid 16035703)
13. Muscelli E, Mari A, Natali A et al (2006) Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 291:E1144-E1150. doi:10.1152/ajpendo.00571.2005 (Pubitemid 44904020)
14. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403. doi:10.1056/NEJMoa012512 (Pubitemid 34437694)
15. Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350. doi:10.1056/NEJM200105033441801 (Pubitemid 32378388)
16. Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393. doi:10.1056/NEJMoa021778 (Pubitemid 36159355)
17. Mosca A, Goodall I, Hoshino T et al (2007) Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med 45:1077-1080. doi:10.1515/CCLM.2007.246 (Pubitemid 47424866)
18. Calanna S, Piro S, Di Pino A et al (2013) Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis. Obesity (Silver Spring) 21:320-325. doi:10.1002/oby.20017
19. Calanna S, Urbano F, Piro S et al (2012) Elevated plasma glu-cose- dependent insulinotropic polypeptide associates with hyperinsulinemia in metabolic syndrome. Eur J Endocrinol 166:917-922. doi:10.1530/EJE-11-0765
20. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470 (Pubitemid 29418240)
21. Kjems LL, Holst JJ, Vølund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386 (Pubitemid 36173193)
22. Tura A, Kautzky-Willer A, Pacini G (2006) Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 72:298-301. doi:10.1016/j.diabres.2005.10.005 (Pubitemid 43729143)
23. Bergman RN, Finegood DT, Kahn SE (2002) The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32(Suppl 3):35-45 (Pubitemid 41704998)
24. Ahrén B, Larsson H (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998-2003. doi:10.1007/s001250100003 (Pubitemid 33124044)
25. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52 (Pubitemid 16162741)
26. Morris DH, Khunti K, Achana F et al (2013) Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 56:1489-1493. doi:10.1007/s00125-013-2902-4
27. Gillett MJ (2009) International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009, 32(7), pp. 1327-1334.
28. Clin Biochem Rev 30:197-200
29. Wolffenbuttel BHR, Herman WH, Gross JL et al (2013) Ethnic differences in glycemic markers in patients with type 2 diabetes. Diabetes Care. doi:10.2337/dc12-2711
30. Jansen H, Stolk RP, Nolte IM et al (2013) Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the lifelines cohort study. J Intern Med 273:283-293. doi:10.1111/joim.12010
31. Shah P, Vella A, Basu A et al (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059 (Pubitemid 32055352)
32. Knop FK, Vilsbøll T, Madsbad S et al (2007) Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50:797-805. doi:10.1007/s00125-006-0566-z (Pubitemid 46355821)
33. Knop FK, Vilsbøll T, Højberg PV et al (2007) Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56:1951-1959. doi:10.2337/db07-0100 (Pubitemid 47195814)